Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.6
Journals
Current Oncology
Special Issues
The Role of Tumor Microenvironment in Pancreatic Cancer Treatment
share announcement

The Role of Tumor Microenvironment in Pancreatic Cancer Treatment

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 2718

Special Issue Editor

Dr. Rui Caetano Oliveira

E-Mail Website
Guest Editor
Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
Interests: animal models of disease; liver transplant pathology; colorectal cancer; liver metastases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The latest Special Issue of our scientific journal explores the critical role of the tumor microenvironment in pancreatic cancer treatment. Pancreatic cancer is known for its aggressive nature, resistance to treatment, and poor prognosis. Therefore, understanding the complex interactions between cancer cells and the microenvironment is crucial for developing effective therapies.

In this Special Issue, we invite you to present your latest research findings, covering various aspects of the tumor microenvironment in pancreatic cancer. Topics range from the role of immune cells and cytokines in modulating the tumor microenvironment to novel approaches for targeting the stroma and enhancing drug delivery.

Through cutting-edge research and innovative approaches, this Special Issue will shed light on the complex and dynamic nature of the tumor microenvironment and its impact on pancreatic cancer treatment. We believe that this Special Issue will be of great interest to researchers, clinicians, and students working in the field of cancer biology and oncology. Join us in exploring the latest advancements in this exciting and rapidly evolving field.

Dr. Rui Caetano Oliveira
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • tumor microenvironment
  • treatment

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 7342 KiB  
Article
Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
by Tej Tummala, Ashley Sanchez Sevilla Uruchurtu, Arielle De La Cruz, Kelsey E. Huntington, Andrew George, Nicholas R. Liguori, Leiqing Zhang, Lanlan Zhou, Abbas E. Abbas, Christopher G. Azzoli and Wafik S. El-Deiry
Curr. Oncol. 2023, 30(11), 9611-9626; https://doi.org/10.3390/curroncol30110696 - 31 Oct 2023
Viewed by 2308
Abstract
Pancreatic cancer is a devastating disease with a poor prognosis. Novel chemotherapeutics in pancreatic cancer have shown limited success, illustrating the urgent need for new treatments. Lurbinectedin (PM01183; LY-01017) received FDA approval in 2020 for metastatic small cell lung cancer on or after [...] Read more.
Pancreatic cancer is a devastating disease with a poor prognosis. Novel chemotherapeutics in pancreatic cancer have shown limited success, illustrating the urgent need for new treatments. Lurbinectedin (PM01183; LY-01017) received FDA approval in 2020 for metastatic small cell lung cancer on or after platinum-based chemotherapy and is currently undergoing clinical trials in a variety of tumor types. Lurbinectedin stalls and degrades RNA Polymerase II and introduces breaks in DNA, causing subsequent apoptosis. We now demonstrate lurbinectedin’s highly efficient killing of human-derived pancreatic tumor cell lines PANC-1, BxPC-3, and HPAF-II as a single agent. We further demonstrate that a combination of lurbinectedin and irinotecan, a topoisomerase I inhibitor with FDA approval for advanced pancreatic cancer, results in the synergistic killing of pancreatic tumor cells. Western blot analysis of combination therapy indicates an upregulation of γH2AX, a DNA damage marker, and the Chk1/ATR pathway, which is involved in replicative stress and DNA damage response. We further demonstrate that the triple combination between lurbinectedin, irinotecan, and 5-fluorouracil (5-FU) results in a highly efficient killing of tumor cells. Our results are developing insights regarding molecular mechanisms underlying the therapeutic efficacy of a novel combination drug treatment for pancreatic cancer. Full article
(This article belongs to the Special Issue The Role of Tumor Microenvironment in Pancreatic Cancer Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop